Swiss National Bank boosted its holdings in Prothena Co. PLC (NASDAQ:PRTA) by 2.2% during the second quarter, Holdings Channel reports. The institutional investor owned 74,200 shares of the biotechnology company’s stock after buying an additional 1,600 shares during the period. Swiss National Bank’s holdings in Prothena were worth $784,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of the business. SG Americas Securities LLC acquired a new position in shares of Prothena in the 1st quarter valued at about $114,000. BNP Paribas Arbitrage SA lifted its stake in shares of Prothena by 309.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 11,061 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 8,360 shares in the last quarter. Moors & Cabot Inc. acquired a new position in shares of Prothena in the 1st quarter valued at about $198,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of Prothena in the 2nd quarter valued at about $215,000. Finally, DekaBank Deutsche Girozentrale lifted its stake in shares of Prothena by 22.1% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,450 shares of the biotechnology company’s stock valued at $240,000 after purchasing an additional 2,800 shares in the last quarter. 96.83% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ PRTA traded down $0.39 during trading on Friday, reaching $8.33. The stock had a trading volume of 14,255 shares, compared to its average volume of 205,480. Prothena Co. PLC has a one year low of $6.71 and a one year high of $14.77. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.95 and a current ratio of 14.94. The stock has a market cap of $332.37 million, a PE ratio of -2.31 and a beta of 2.18. The firm’s 50 day moving average price is $8.59 and its two-hundred day moving average price is $10.36.
PRTA has been the topic of several recent research reports. ValuEngine raised Prothena from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Barclays restated a “sell” rating and set a $9.00 price objective on shares of Prothena in a report on Friday, May 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a report on Thursday, May 16th. BidaskClub downgraded Prothena from a “sell” rating to a “strong sell” rating in a report on Thursday, August 15th. Finally, Zacks Investment Research upgraded Prothena from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Wednesday, June 19th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Prothena currently has a consensus rating of “Hold” and a consensus target price of $11.26.
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.
Featured Story: Using other technical indicators with support levels
Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. PLC (NASDAQ:PRTA).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.